Real-World Evidence That As-Needed Dosing with Bimekizumab in Patients with Psoriasis Is Safe and Effective over Time

Background/Objectives: Despite substantial progress in the management of psoriasis, evidence on as-needed dosing strategies for biologic therapies remains scarce. In this context, the present study aimed to assess the effectiveness of a previously defined as-needed bimekizumab (BKZ) dosing regimen in a larger cohort of patients with psoriasis, as well as to identify clinical factors associated with treatment response. Methods: In this retrospective study, medical records of 64 patients with moderate-to-severe psoriasis treated with BKZ between May 2023 and November 2025 at a specialized psoriasis unit in Madrid, Spain, were reviewed. Patients followed an off-label, as-needed dosing regimen, consisting of two initial 320 mg doses at Weeks 0 and 4, with subsequent administrations only upon loss of a PASI 90 response. The primary outcome was the proportion of patients achieving and maintaining optimal disease control (PASI 90) over time. The duration of treatment effect was defined as the interval between the second dose and loss of PASI90 in the absence of further treatment. Safety outcomes were also evaluated. Results: A total of 59 out of 64 patients achieved a PASI 90 response after the initial two BKZ doses, and all maintained disease control with the as-needed dosing strategy over time. On average, patients received approximately one-third of the doses expected under the standard dosing regimen. The mean duration of treatment effect following the second dose was approximately 24 weeks. Systemic and bio-naïve patients presented the longest treatment effect duration under the as-needed dosing regimen. Oral candidiasis was reported in two patients and resolved without complications. Conclusions: This study reinforces previous evidence supporting the effectiveness of an as-needed BKZ dosing strategy, particularly in patients naïve to systemic and biologic therapies for psoriasis. Nevertheless, larger prospective studies are required to confirm these findings.

Authors

Institutions

Publication Details

Journal
Journal of Personalized Medicine
Published
2026-04-27
DOI
https://doi.org/10.3390/jpm16050234
Primary Topic
Psoriasis: Treatment and Pathogenesis
Type
article
Field-Weighted Citation Impact
0.00

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Real-World Evidence That As-Needed Dosing with Bimekizumab in Patients with Psoriasis Is Safe and Effective over Time

Nicholas Brownstone, Carlota Abbad‐Jaime de Aragón, Inés Perales-Sánchez, Pedro Jaén et al.
Journal of Personalized Medicine
Psoriasis: Treatment and Pathogenesis
article

Real-World Evidence That As-Needed Dosing with Bimekizumab in Patients with Psoriasis Is Safe and Effective over Time

Nicholas Brownstone, Carlota Abbad‐Jaime de Aragón, Inés Perales-Sánchez, Pedro Jaén, E. Berná-Rico, María Davó-Mogica, Lluis Puig, Pablo de la Cruz-Anaya, Andrew Blauvelt, Alvaro González-Cantero, Inés Díaz-Ruiz
article en

Abstract

Background/Objectives: Despite substantial progress in the management of psoriasis, evidence on as-needed dosing strategies for biologic therapies remains scarce. In this context, the present study aimed to assess the effectiveness of a previously defined as-needed bimekizumab (BKZ) dosing regimen in a larger cohort of patients with psoriasis, as well as to identify clinical factors associated with treatment response. Methods: In this retrospective study, medical records of 64 patients with moderate-to-severe psoriasis treated with BKZ between May 2023 and November 2025 at a specialized psoriasis unit in Madrid, Spain, were reviewed. Patients followed an off-label, as-needed dosing regimen, consisting of two initial 320 mg doses at Weeks 0 and 4, with subsequent administrations only upon loss of a PASI 90 response. The primary outcome was the proportion of patients achieving and maintaining optimal disease control (PASI 90) over time. The duration of treatment effect was defined as the interval between the second dose and loss of PASI90 in the absence of further treatment. Safety outcomes were also evaluated. Results: A total of 59 out of 64 patients achieved a PASI 90 response after the initial two BKZ doses, and all maintained disease control with the as-needed dosing strategy over time. On average, patients received approximately one-third of the doses expected under the standard dosing regimen. The mean duration of treatment effect following the second dose was approximately 24 weeks. Systemic and bio-naïve patients presented the longest treatment effect duration under the as-needed dosing regimen. Oral candidiasis was reported in two patients and resolved without complications. Conclusions: This study reinforces previous evidence supporting the effectiveness of an as-needed BKZ dosing strategy, particularly in patients naïve to systemic and biologic therapies for psoriasis. Nevertheless, larger prospective studies are required to confirm these findings.

Journal of Personalized MedicineVol. 16(5)
Universitat Autònoma de Barcelona (ES), Universidad Francisco de Vitoria (ES), Hospital de Sant Pau (ES), Maryland Department of Natural Resources (US), Instituto Ramón y Cajal de Investigación Sanitaria (ES), Hospital San Pedro (ES), Servicio de Salud de Castilla La Mancha (ES), Hospital Nacional de Parapléjicos (ES), Icahn School of Medicine at Mount Sinai (US)
Amgen, Bristol-Myers Squibb, Eli Lilly and Company, Pfizer, Sanofi, Biogen, Regeneron Pharmaceuticals, Incyte, Galderma, Sun Pharma, LEO Pharma, Samsung, UCB Pharma
Good health and well-being
Openalex Percentile: Top 18%
Psoriasis: Treatment and Pathogenesis
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.